Phuturdex › Diseases › Urologic Diseases
Drugs in development · updated 30 October 2026
Urologic Diseases: drugs in development
As of 30 October 2026 there are 15 active clinical trials (recruiting or ongoing, phases I–III) on 16 drugs for urologic Diseases. 4 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| ZigakibartBION-1301 | III | 3 | NCT06858319 |
| BHV-1400 | III | 2 | NCT07642050 |
| JADE101 | III | 2 | NCT07902817 |
| SasanlimabZumrad® | II | 1 | NCT05241340 |
Sorted by most advanced phase and number of active trials.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| AtrasentanVanrafia® | III | 2 | NCT07498335 |
| CisplatinCis Platinum, Cisplatine | III | 1 | NCT07566156 |
| DCR-PHXC | III | 1 | NCT04042402 |
| Enfortumab VedotinPadcev® | III | 1 | NCT07566156 |
| Fluorouracil5-Fluorouracil, Adrucil | III | 1 | NCT07566156 |
| GemcitabineGemcitabin, Gemzar | III | 1 | NCT07566156 |
| Mitomycin CMitomycin, Jelmyto | III | 1 | NCT07566156 |
| OnabotulinumtoxinABotox, Botox Cosmetic® | II–III | 1 | NCT05878951 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 1 | NCT07566156 |
| AtaciceptTrutakna® | II | 1 | NCT06674577 |
| Methenamine hippurateHiprex® | II | 1 | NCT07202949 |
| Testosterone cypionateAzmiro® | I | 1 | NCT04731376 |
Sorted by most advanced phase and number of active trials.
All 16 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Renal cell carcinoma 228 drugs
- Bladder neoplasm 185 drugs
- Chronic renal insufficiency 104 drugs
- Non-small-cell lung carcinoma 726 drugs
- Kidney neoplasm 92 drugs
- Transitional cell carcinoma 146 drugs
- Melanoma 352 drugs
- Non-muscle invasive bladder neoplasm 50 drugs
- IgA glomerulonephritis 48 drugs
- Lupus nephritis 64 drugs
- Colorectal neoplasm 534 drugs
- Metastasis 493 drugs
Broader categories
- Female urogenital diseases and pregnancy complications 3 drugs
- Female urogenital disease 11 drugs
- Male urogenital disease 19 drugs
- Urogenital Diseases 16 drugs
- Renal Insufficiency 51 drugs
- Immune System Diseases 54 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D014570 “Urologic Diseases”.